IL140848A - Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate - Google Patents

Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate

Info

Publication number
IL140848A
IL140848A IL14084899A IL14084899A IL140848A IL 140848 A IL140848 A IL 140848A IL 14084899 A IL14084899 A IL 14084899A IL 14084899 A IL14084899 A IL 14084899A IL 140848 A IL140848 A IL 140848A
Authority
IL
Israel
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
pharmaceutical compositions
pharmaceutical composition
Prior art date
Application number
IL14084899A
Other languages
English (en)
Other versions
IL140848A0 (en
Original Assignee
Burzynski Stanislaw R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burzynski Stanislaw R filed Critical Burzynski Stanislaw R
Publication of IL140848A0 publication Critical patent/IL140848A0/xx
Publication of IL140848A publication Critical patent/IL140848A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14084899A 1998-07-23 1999-07-02 Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate IL140848A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (2)

Publication Number Publication Date
IL140848A0 IL140848A0 (en) 2002-02-10
IL140848A true IL140848A (en) 2005-05-17

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14084899A IL140848A (en) 1998-07-23 1999-07-02 Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate

Country Status (20)

Country Link
US (2) US6258849B1 (de)
EP (1) EP1098643B1 (de)
JP (2) JP2002521329A (de)
KR (4) KR100414587B1 (de)
CN (3) CN100400039C (de)
AT (1) ATE257378T1 (de)
AU (1) AU759278B2 (de)
BR (1) BR9912356A (de)
CA (1) CA2336945C (de)
DE (1) DE69914084T2 (de)
DK (1) DK1098643T3 (de)
EA (1) EA004179B1 (de)
ES (1) ES2214866T3 (de)
ID (1) ID28160A (de)
IL (1) IL140848A (de)
NZ (1) NZ509244A (de)
PL (1) PL213698B1 (de)
PT (1) PT1098643E (de)
WO (1) WO2000004894A2 (de)
ZA (1) ZA200100622B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
EP1642885B1 (de) 2000-08-29 2009-11-11 Biocon Limited Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
HUE028158T2 (en) * 2004-07-07 2016-12-28 Biocon Ltd Synthesis of bound immunoregulatory compounds
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
ES2448549T3 (es) * 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (de) 2009-06-08 2014-10-15 UCL Business PLC Behandlung von pfortaderhochdruck mittels l-ornithin-phenylacetat
EP2625162B1 (de) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Verfahren zur herstellung von l-ornithin-phenyl-acetat
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
KR20230124107A (ko) * 2017-06-12 2023-08-24 스탠니슬로우 알 벌진스키 연수막 질환의 치료 방법
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
WO1997042939A1 (en) 1996-05-14 1997-11-20 Burzynski Research Inst Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
CA2336945A1 (en) 2000-02-03
HK1037142A1 (en) 2002-02-01
US6943192B2 (en) 2005-09-13
KR20030027088A (ko) 2003-04-03
EP1098643B1 (de) 2004-01-07
CN1660061A (zh) 2005-08-31
CN100400039C (zh) 2008-07-09
DE69914084T2 (de) 2004-10-28
IL140848A0 (en) 2002-02-10
WO2000004894A3 (en) 2000-04-27
EA200100168A1 (ru) 2001-08-27
JP2011051993A (ja) 2011-03-17
CN1319010A (zh) 2001-10-24
CN1191064C (zh) 2005-03-02
AU759278B2 (en) 2003-04-10
ID28160A (id) 2001-05-10
AU4854299A (en) 2000-02-14
KR100417100B1 (ko) 2004-02-05
JP2002521329A (ja) 2002-07-16
PL213698B1 (pl) 2013-04-30
ES2214866T3 (es) 2004-09-16
US6258849B1 (en) 2001-07-10
WO2000004894A2 (en) 2000-02-03
KR100417101B1 (ko) 2004-02-05
EA004179B1 (ru) 2004-02-26
BR9912356A (pt) 2001-04-17
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
DE69914084D1 (de) 2004-02-12
ATE257378T1 (de) 2004-01-15
KR20030027089A (ko) 2003-04-03
PL345959A1 (en) 2002-01-14
KR100414587B1 (ko) 2004-01-13
CN1605334A (zh) 2005-04-13
KR20030027087A (ko) 2003-04-03
ZA200100622B (en) 2002-06-26
CA2336945C (en) 2008-11-18
PT1098643E (pt) 2004-05-31
US20010044466A1 (en) 2001-11-22
EP1098643A2 (de) 2001-05-16
NZ509244A (en) 2004-02-27
DK1098643T3 (da) 2004-05-24

Similar Documents

Publication Publication Date Title
PL345959A1 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
AU1537095A (en) Therapeutic agents containing thyroid hormones
YU54499A (sh) Farmaceutski preparat za primenu na mukozu
ATE220917T1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
GEP20012390B (en) Benzonaphthyridines as Bronchial Therapeutics
EP0911331A3 (de) Substutierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen, und Anwendungsmethoden
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
SE8204873D0 (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
JPS56138110A (en) Suppository containing citric acid or salt thereof
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
JPS54105221A (en) Preparation of stable concentrated dopa injection
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere
ATE360429T1 (de) Krebsmittel
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
FR2653665B1 (fr) Extrait soluble dans l'eau de pittosporaceae, ses applications comme medicament dans le traitement des diabetes et des affections hepatiques et procedes de preparation.
RO102780B1 (ro) Metoda de anestezie generala
UA30393A (uk) Спосіб лікування коронарного атеросклерозу
JPS5524150A (en) Anti-malignant-tumor agent
JPS5569510A (en) Carcinostatic agent

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired